[The inhibitory action of the antisense oligodeoxynucleotide to the expression of vascular endothelial growth factor by radiotherapy in a prostate cancer cell line].
OBJECTIVE
To investigate mechanism for the increasing level of serum vascular endothelial growth factor(VEGF) in tumour patients during radiotherapy and the inhibitory action of the antisense oligodeoxynucleotide (AS-ODN) to the expression of VEGF protein by radiotherapy in the prostate cancer cell line (PC3M).


METHODS
To observe the changes of serum VEGF in the prostate cancer patients during radiotherapy dynamically and the inhibitory action of the antisense oligodeoxynucleotide to the expression of VEGF by radiotherapy in PC3M.


RESULTS
The changes of serum VEGF in three patients receiving radiotherapy had been observed continuously. The levels of serum VEGF began to increase when the patients received radiotherapy and rised up to peak value after fifteen days, then declined to the range of pre-radiotherapy. Irradiating the PC3M cells with X-rays significantly increased the VEGF expression and secretion. The expression of VEGF protein in the group treated by VEGF AS-ODNs and X-ray irradiation decreased significantly than the group treated only by X-ray irradiation.


CONCLUSIONS
The induction of VEGF protein expression by X-ray irradiation in tumor cells may result in the increasing of the VEGF in the prostate cancer patients during radiotherapy and the induction can be blocked by VEGF AS-ODNs.
Meng
Dong-Ya
DY
Clinical Laboratory, General Hospital of Shenyang Military Region, Shenyang, Liaoning 110015, China.
Xue
Wen-Cheng
WC
Hu
Xiao-Fang
XF
Wang
Yi-Nan
YN
Luo
Jun
J
D016373:DNA, Antisense / Q000494:pharmacology*; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors* / Q000097:blood / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects* / Q000528:radiation effects; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood / Q000235:genetics; D008222:Lymphokines / Q000037:antagonists & inhibitors* / Q000097:blood / Q000235:genetics; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood* / Q000473:pathology; D011878:Radiotherapy / Q000009:adverse effects; D014407:Tumor Cells, Cultured; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016373:DNA, Antisense; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors